Prostate cancer drug not prescribed because of cost

The Prostate Cancer Charity says that some men are being denied the drug docetaxel (Taxotere) simply on cost grounds.

Prostate cancer cells
Prostate cancer cells
Docetaxel was first licensed for the treatment of breast cancer, but was found to improveoverall survival, compared with the standard treatments, in patients with prostate cancer who had not responded to hormone therapy

NICE approved the use of docetaxel in June of this year, but a course of treatment costs approximately £7,000.

John Neate, chief executive of the Prostate Cancer Charity told the BBC: ‘It cannot be acceptable that men and their families who are already having to deal with the tough news of a prostate cancer diagnosis, have to wrestle with NHS bureaucracy at the same time.’

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus